21 Dec

This Drug May Become a Long-Term Growth Driver for Celgene

WRITTEN BY Margaret Patrick FEATURED IN Company News, Insights, & Analysis

AG-221’s growth prospects

In addition to its robust product portfolio, Celgene (CELG) is also involved in developing promising investigational drugs across multiple therapeutic areas. In accordance with its 2010 collaboration agreement, Celgene licensed enasidenib (or AG-221) from Agios Pharmaceuticals in June 2014.

Celgene expects to submit a new drug application (or NDA) to the FDA seeking approval for AG-221 for patients suffering from relapsed and refractory acute myeloid leukemia (or RR-AML) by end of 2016. The application will be based on data obtained from Phase 1 and 2 studies that evaluated AG-221 in patients suffering from advanced hematologic malignancies and the isocitrate dehydrogenase-2 (or IDH-2) mutation.

This Drug May Become a Long-Term Growth Driver for Celgene

If the FDA approves AG-221 for the treatment of AML, it should have a positive impact on the share prices of Celgene and the iShares Core S&P 500 ETF (IVV). Celgene makes up ~0.47% of IVV’s total portfolio holdings.

Significant unmet demand

The above diagram shows AML survival rates differentiated by patients’ ages. Due to limited existing treatment options, the average five-year survival rate is in the range of 20%–25%. However, AML mostly afflicts older adults with a median age of 68–72. In such a scenario, the five-year survival rate dips further to the range of 10%–20%, mainly due to the inability of older patients to tolerate intensive chemotherapy or bone marrow transplants.

Since IDH-2 mutations are witnessed by ~10%–15% of AML cases, AG-221 could prove to be an effective treatment option for these patients. The drug was well tolerated and effective in its clinical trials. Celgene is also exploring the drug in a front-line AML indication. It’s thus expected to enable the company to pose strong competition to other hematologic oncology players such as AbbVie (ABBV), Merck & Co. (MRK), and Amgen (AMGN).

In the next article, we’ll analyze growth prospects for Otezla in 2016.

Latest articles

Verizon Communications stock (VZ) closed down 2.09% on Tuesday after the leading US mobile carrier reported mixed results for the first quarter of 2019 before the market bell yesterday.

24 Apr

Nokia’s Patent Business Is Put On the Spot

WRITTEN BY Rachel Gunter

Several European auto companies want Nokia’s (NOK) patent business subjected to an antitrust probe.

The first-quarter semiconductor earnings season has begun, and the stock market is showing bullish sentiment as investors buy ahead of earnings releases.

Netflix (NFLX) is working its way through a series of price increases in several markets, including the United States and parts of Europe.

Netflix (NFLX) is aiming to add 14.6 million paying subscribers in the first six months of 2019.

Earlier today, the second-largest US automaker, Ford Motor Company (F), announced a plan to invest $500 million in Plymouth-based automotive company Rivian.